CN101708204A - Medicinal composition for treating cardio-cerebrovascular diseases - Google Patents
Medicinal composition for treating cardio-cerebrovascular diseases Download PDFInfo
- Publication number
- CN101708204A CN101708204A CN200910153986A CN200910153986A CN101708204A CN 101708204 A CN101708204 A CN 101708204A CN 200910153986 A CN200910153986 A CN 200910153986A CN 200910153986 A CN200910153986 A CN 200910153986A CN 101708204 A CN101708204 A CN 101708204A
- Authority
- CN
- China
- Prior art keywords
- extract
- pharmaceutical composition
- radix notoginseng
- folium ginkgo
- aspirin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal composition for treating cardio-cerebrovascular diseases, which comprises the following raw materials in percentage by weight: 0.1 to 99.8 percent of ginkgo biloba P.E; 0.1 to 99.8 percent of sanchi extract; and 0.1 to 99.8 percent of aspirin. By utilizing the synergistic action of the ginkgo biloba P.E, the sanchi extract and the aspirin, the medicinal composition can effectively improve cardio-cerebrovascular circulation after the cerebral infarction and the miocardial infarction, dilate cardiac and cerebral vessels, and increase cardio-cerebral blood flow volume, and also can effectively improve microcirculation and reduce damage caused by ischemia-reperfusion after the cerebral infarction and the miocardial infarction.
Description
Technical field
The present invention relates to field of medicinal compositions, be specifically related to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease.
Background technology
Cardiovascular and cerebrovascular disease is meant hemorrhage or what form that thrombosis causes is the disease of main clinical manifestation with the cerebral ischemic injury symptom owing to rupture of blood vessel in brain, claims cerebrovascular accident or apoplexy again, is commonly called as to be apoplexy.This disease is common in crowd's above middle age acute attack, wherein 70%～80% patient is owing to reasons such as cerebral arteriosclerosis make the cerebral arteries luminal stenosis, blood flow reduces or total blockage, the brain blood circulation obstacle, impaired and a series of symptoms (as ischemic cerebrovascular) of derivation of cerebral tissue, disturbance of consciousness and quadriplegia can take place in severe patient, are to cause human dead and disabled principal disease at present.
The formation of thrombosis mainly contains three big essential factors, i.e. the pathological change of blood vessel wall, blood flow and blood, and arterial thrombus almost all forms on arteriosclerosis or atherosclerotic basis clinically.Exist in the blood and solidify and the solid composition of anticoagulant, fibrinolytic with press down fibrinolytic composition, unbalance when its appearances, will cause established thrombosis not dissolve, continue existence.In addition, cardiovascular system diseases and hyperglycemia, hyperlipidemia all can cause blood viscosity to increase, and strengthen resistance of blood flow and make slow blood flow, very easily form thrombosis.Thrombosis causes blood vessel embolism, so that cerebral infarction, myocardial infarction, coronary heart disease, angina pectoris etc.
At the formation reason of cardiovascular and cerebrovascular disease, prior treatment method is mainly thrombolytic therapy and brain protection therapy, but thromboembolism, and in the time of the recovery organization organ blood flow, generation reperfusion injury that will be in various degree causes more serious consequence.And Western medicine preparation at present commonly used mainly is that anticoagulant preparation (is representative with aspirin) and fibrinolysis enhancing preparation are (as various fibrinolysins, urokinase, t-PA etc.), though Chinese medicine preparation has certain curative effect to diseases of cardiovascular and cerebrovascular systems, but only fresh thrombus there is curative effect preferably, especially with sequela person, curative effect is not very desirable to the old thrombosis, and all can't solve the reperfusion injury that thrombolytic is produced simultaneously preferably.
Folium Ginkgo is the leaf of Ginkgoaceae plant Ginkgo biloba Ginkgo biloba, and nature and flavor hardship, puckery, flat, major function are that activating blood circulation to dissipate blood stasis, collateral dredging are active.Folium Ginkgo extract is widely used in treating cardiovascular and cerebrovascular disease and sequela thereof etc.Modern pharmacology studies have shown that Folium Ginkgo extract has microcirculation improvement and metabolism, removes free radical and antioxidation, anti-platelet activating factor, effects such as infection.Ginkalide B (ginkgolide B; GB) be one of the main active of Folium Ginkgo extract; it is the strong specific platelet activating factor of a class (PAF) antagonist; suppress all kinds of unusual inflammatory reaction and the thromboembolism formation that ischemia causes by suppressing the PAF function; suppress disengaging of free radical, thereby protection myeloid tissue avoids damage.In addition, studies show that GB may have the effect of analog growth factor, promote the self-sow of neurocyte, and under many pathologic conditions, can also alleviate nerve cell damage and apoptosis, bring into play tangible neuroprotective.As seen, ginkalide B can control inflammation and can promote neuranagenesis.
Radix Notoginseng [Panax notoginseng (Burk.) F.H.Chen] beginning is stated from Compendium of Material Medica, its main effective ingredient is a Radix Notoginseng total arasaponins, has the dissipating blood stasis hemostasis, the effect of subduing swelling and relieving pain can be used for treating spitting of blood, haematemesis, epistaxis, has blood in stool, metrorrhagia, traumatic hemorrhage, breast ventral spine pain, falls and swell and ache etc.Development along with modern medicine and pharmacology research; find that Radix Notoginseng not only has good hemostasis, blood circulation promoting and blood stasis dispelling, the active two-way pharmacological action of promoting blood circulation; also has tangible blood tonification effect; can promote all kinds of blood cell merisis such as erythrocyte in the blood, leukocyte, platelet; increase number; the effect that keeps normal level, have antithrombotic, protection cardiac muscle simultaneously and prevent brain tissue impairment and expand blood vessel, increase brain and arteria coronaria blood flow, multiple pharmacological effect such as blood fat reducing, blood pressure lowering, analgesia, antiinflammatory, removing free radical.
Aspirin (Aspirin) has another name called aspirin, it is the time-honored nonsteroidal antiinflammatory drug of using always, has antipyretic-antalgic, antiinflammatory rheumatism and anti-platelet aggregation effect, early stage clinical headache, rheumatic fever, rheumatic arthritis and the gout of being used for, be expanded into the antiplatelet drug that is used for the cardiovascular and cerebrovascular disease primary prevention afterwards clinically, simultaneously also effective for the secondary prevention of myocardial infarction and ischemic vascular disease.General low dose of aspirin can be used for preventing the outbreak of cardiovascular and cerebrovascular disease and transience ischemic diseases, as cerebral thrombosis, coronary heart disease, myocardial infarction etc.
Summary of the invention
The invention provides a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, utilize Folium Ginkgo extract, Radix Notoginseng extract and aspirin three's synergism, can effectively improve the cardiovascular and cerebrovascular circulation after cerebral infarction, the myocardial infarction, the expansion cardiovascular and cerebrovascular vessel, increase the heart and brain blood flow, while is microcirculation improvement effectively, alleviates cerebral infarction, the damage that ischemia-reperfusion causes after the myocardial infarction.
A kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is made up of following raw materials by weight percent: Folium Ginkgo extract 0.1%～99.8%, Radix Notoginseng extract 0.1%～99.8% and aspirin 0.1%～99.8%.
In order to reach therapeutic effect better, preferred: the pharmaceutical composition of described treatment cardiovascular and cerebrovascular disease preferably is made up of following raw materials by weight percent: Folium Ginkgo extract 15%～35%, Radix Notoginseng extract 15%～35% and aspirin 30%～70%; Further preferably form: Folium Ginkgo extract 15%, Radix Notoginseng extract 15% and aspirin 70% by following raw materials by weight percent, perhaps form by following raw materials by weight percent: Folium Ginkgo extract 33.0%, Radix Notoginseng extract 34.0% and aspirin 33.0%, perhaps form: Folium Ginkgo extract 26%, Radix Notoginseng extract 26% and aspirin 48% by following raw materials by weight percent.
The weight percentage of total flavones is 24%～90% in the described Folium Ginkgo extract, the weight percentage 6%～50% of the total lactone of Semen Ginkgo, and the total ginkgolic acids weight content is less than 10ppm.
Described Folium Ginkgo extract can adopt the commercially available prod, also can prepare voluntarily, and its preparation method can specifically comprise step with reference to the record in 2005 editions Pharmacopoeias of the People's Republic of China:
Get Folium Ginkgo and pulverize the back ethanol extraction, extracting solution reclaims and is added on the macroporous adsorptive resins after ethanol also concentrates, and water and ethanol elution are collected ethanol elution successively, reclaim ethanol, and drying promptly gets Folium Ginkgo extract.
The weight percentage of Radix Notoginseng total arasaponins is 55%～90% in the described Radix Notoginseng extract.
Described Radix Notoginseng extract can adopt the commercially available prod, also can prepare voluntarily, and its preparation method comprises step:
Get Radix Notoginseng and pulverize, use ethanol extraction, extracting solution adds water, cold preservation 24 hours after reclaiming ethanol, filter, filtrate is added on the macroporous adsorptive resins of handling well with soak with ethanol, and water and ethanol elution are collected ethanol elution successively, reclaim ethanol, drying promptly gets Radix Notoginseng extract.
The pharmaceutical composition of described treatment cardiovascular and cerebrovascular disease can become any dosage form in the existing pharmaceutical dosage forms such as tablet, capsule, drop pill, granule, suppository according to prior art for preparing.
Described aspirin meets that the quality standard of aspirin gets final product in the Pharmacopoeia of the People's Republic of China.
The present invention has following beneficial effect:
Compare with the medicine of existing treatment cardiovascular and cerebrovascular disease, pharmaceutical composition of the present invention utilizes Folium Ginkgo extract, Radix Notoginseng extract and aspirin three's synergism, specifically, be with the total flavones in the Folium Ginkgo, compositions such as the total lactone of Semen Ginkgo, compositions such as the Radix Notoginseng total arasaponins in the Radix Notoginseng add aspirin can give full play to the Chinese medicine compound multipath, the synergism of many target spots, can effectively improve cerebral infarction, cardiovascular and cerebrovascular circulation after the myocardial infarction, the expansion cardiovascular and cerebrovascular vessel, increase the heart and brain blood flow, while is microcirculation improvement effectively, alleviates cerebral infarction, the more serious damage that ischemia-reperfusion causes after the myocardial infarction.
Find through test, under the situation of one times of taking dose decline, pharmaceutical composition of the present invention is than singly using with the dosage Folium Ginkgo extract, singly use with the dosage Radix Notoginseng extract, singly use with the dosage aspirin, singly using with the dosage Folium Ginkgo extract and add Radix Notoginseng extract, singly use to add aspirin or singly use with the dosage Folium Ginkgo extract and add aspirin with the dosage Radix Notoginseng extract therapeutic effect of cerebral ischemia cerebral infarction is all improved a lot, as seen, Folium Ginkgo extract, Radix Notoginseng extract and aspirin compatibility have been share good synergism, and curative effect is significantly improved.In addition, pharmaceutical composition of the present invention is when heightening the effect of a treatment, and taking dose significantly reduces, and has reduced the toxicity of medicine, has increased the safety of medication.
The specific embodiment
Embodiment 1～6
Get exsiccant Folium Ginkgo and pulverize the back ethanol extraction, extracting solution reclaims and is added on the macroporous adsorptive resins of handling with soak with ethanol after ethanol also concentrates, and water and ethanol elution are collected ethanol elution successively, reclaim ethanol, and drying promptly gets Folium Ginkgo extract.After testing, the weight percentage of total flavones is 26% in the Folium Ginkgo extract, and the weight percentage 6.5% of the total lactone of Semen Ginkgo, the weight percentage of total ginkgolic acids are 5ppm.
Getting Radix Notoginseng pulverizes, add ethanol, reflux, extract, 3 times, each 2 hours, extracting solution reclaims ethanol to there not being the ethanol flavor, add water to every milliliter and be equivalent to 2 gram crude drugs, cold preservation 24 hours filters, filtrate is added on the macroporous adsorptive resins of handling well with soak with ethanol, processing procedure is for using soak with ethanol 48 hours, and the dress post adds 5 times of water gagings with ethanol elution to eluent and do not become turbid.Water and ethanol elution are collected ethanol elution successively, reclaim ethanol, and drying promptly gets Radix Notoginseng extract.After testing, the weight percentage of Radix Notoginseng total arasaponins is 58%.
Above-mentioned Folium Ginkgo extract, Radix Notoginseng extract and aspirin are promptly got the pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease after by the proportioning mix homogeneously in the table 1.
Table 1
| Embodiment | Folium Ginkgo extract | Radix Notoginseng extract | Aspirin |
| ??1 | ??1.5Kg | ??1.5Kg | ??7Kg |
| ??2 | ??3.3Kg | ??3.4Kg | ??3.3Kg |
| ??3 | ??2.6Kg | ??2.6Kg | ??4.8Kg |
| ??4 | ??0.1Kg | ??0.1Kg | ??99.8Kg |
| ??5 | ??99.8Kg | ??0.1Kg | ??0.1Kg |
| ??6 | ??0.1Kg | ??99.8Kg | ??0.1Kg |
Folium Ginkgo extract, Radix Notoginseng extract and aspirin compatibility are to the experimentation of cerebral ischemic reperfusion in rats protective effect
Requirement according to apoplexy new Chinese medicine pharmacodynamic study guide principle, need carry out curing mainly relevant Pharmacodynamic test of active extract: with rat brain focal cerebral ischemia injury re-perfusion model with function, determine the best compatibility dosage of Folium Ginkgo extract, Radix Notoginseng extract and aspirin component, prove its treatment synergism cardiovascular and cerebrovascular disease.
1. material
1.1 experimental animal
The SD rat, cleaning level, male, body weight 240 ± 20g is provided by Zhejiang Province's Experimental Animal Center, the quality certification number: SCXK (Zhejiang) 2008-0033.
1.2 medicine and reagent
No. 1 group: Folium Ginkgo extract is divided into 30.0mg/kg, 15.0mg/kg, 2 dosage groups by the taking dose of SD rat;
No. 2 groups: Radix Notoginseng extract is divided into 30.0mg/kg, 15.0mg/kg, 2 dosage groups by the taking dose of SD rat;
No. 3 groups: aspirin is divided into 15.0mg/kg, 7.5mg/kg, 2 dosage groups by the taking dose of SD rat;
No. 4 groups: the mixture of Folium Ginkgo extract and Radix Notoginseng extract (weight ratio is 1: 1) is provided with 15mg/kg, 1 dosage group by the taking dose of SD rat;
No. 5 groups: the mixture of Folium Ginkgo extract and aspirin (weight ratio is 1: 1) is provided with 15mg/kg, 1 dosage group by the taking dose of SD rat;
No. 6 groups: the mixture of Radix Notoginseng extract and aspirin (weight ratio is 1: 1) is provided with 15mg/kg, 1 dosage group by the taking dose of SD rat;
1 group of embodiment: get the pharmaceutical composition of embodiment 1 preparation, 1 dosage group of 15mg/kg is set by the taking dose of SD rat;
2 groups of embodiment: get the pharmaceutical composition of embodiment 2 preparation, 1 dosage group of 15mg/kg is set by the taking dose of SD rat;
3 groups of embodiment: get the pharmaceutical composition of embodiment 3 preparation, 1 dosage group of 15mg/kg is set by the taking dose of SD rat.
Red tetrazolium (TTC), the East China Normal University chemical plant produces, lot number: 20081217; K
2HPO
4, east, Chengdu aurification reagent company limited is produced lot number: 20070615; Chloral hydrate, Chemical Reagent Co., Ltd., Sinopharm Group produces, lot number: T20070919; Formaldehyde, Quzhou hugeization reagent company limited is produced, lot number: 20080401; Disinfectant tamed iodine, the strong precious articles for use factory that prevents epidemic in Nanchang produces lot number: 20080908.Superoxide dismutase (SOD), malonaldehyde (MDA) test kit builds up bio-engineering research by Nanjing provides, and lot number is respectively: 20090924,20090924.
1.3 experimental apparatus
The HZ-9212S constant temperature oscillator, Taicang science and education equipment factory product; PB1501-L type electronic balance, Mettler-Toledo Instrument's product; AL104 type electronic balance, Mettler-Toledo Instrument's product.
2. test method
With reference to the developmental pharmacology research method (Lv Qiujun chief editor, Chemical Industry Press, 2007,239-240) and medical research animal model commonly used (Miao Mingsan, Zhu Feipeng chief editor, the People's Health Publisher, 2007,111-112).
2.1 grouping and administration
The SD rat is divided into 14 groups at random, every group 10: i.e. sham operated rats, model group, No. 1 group 30mg/kg group, No. 1 group 15mg/kg, No. 2 group 30mg/kg, No. 2 group 15mg/kg, No. 3 group 15mg/kg, No. 3 group 7.5mg/kg, No. 4 groups, No. 5 groups, No. 6 groups, 1 group of embodiment, 3 groups of 2 groups of embodiment and embodiment.Gastric infusion, once a day, 1h modeling after the administration 3 times is administered once after the modeling again, and sham operated rats and model group wait the distilled water of capacity.
2.2 the preparation of middle cerebral artery ischemia-reperfusion model (MCAO)
The chloral hydrate solution of rats by intraperitoneal injection 10% is anaesthetized (350mg/kg), it is fixing to lie on the back, separate right carotid (CCA), internal carotid artery (ICA) and external carotid artery (ECA), ligation ECA and CCA, after closing the ICA distal end with bulldog clamp folder, make a kerf in the common carotid artery place of distance ECA and the about 0.5cm of ICA crotch rapidly, insert the nylon wire that an end is heated into smooth, spherical, insertion depth is 18 ± 0.5mm, realizes that middle cerebral artery occlusion causes cerebral ischemia.Ligation porch, nylon wire are stayed about 1cm outward, skin suture, lift gently after 2 hours institute's the end of a thread that stays to resistance slightly to realize that middle cerebral artery pours into again, be cerebral ischemia reperfusion model (MCAO) group, be called for short model group.Sham operated rats is except a ligation right side CCA, and all the other operate all same model group.
2.3 function of nervous system's scoring (being the nervous symptoms score value)
In postoperative 6h the rat behavior obstacle is marked: represented the impassivity afunction in 0 minute, movable normal; Representative in 1 fen can not full extension the left side fore paw; Turn-take on the left of occurring when representative was creeped in 2 minutes (knock into the back and levy); Health arrives to the right during representative walking in 3 fens; Representative in 4 fens can not be walked loss of consciousness.
2.4 the cerebral ischemia infarct size is measured
Get brain in postoperative 24h broken end, remove olfactory bulb, cerebellum and low brain stem after, get operation side brain, crownly be cut to 5 at 4 ℃, and rapidly the brain sheet placed the TTC dye liquor, 37 ℃ of lucifuge temperature were incubated 30 minutes, took out to be placed on the 24h that keeps in Dark Place in 10% formalin.The non-infarcted region in dyed back is a rose, and infarcted region is a white.White organized carefully to dig down weigh, the percentage ratio that accounts for full brain weight with infarction tissue's weight is as the cerebral infarction scope, and computing formula is as follows:
2.5 SOD in serum, MDA measure
24 hours rat anesthesia abdominal aortic bloods of postoperative behind the centrifugal 10min of 3500r/min, are got supernatant 30 μ L, press SOD and measure test kit explanation mensuration serum activity of SOD.Get supernatant 0.1mL, press MDA and measure test kit explanation mensuration Content of MDA.
3. add up
The data SPSS statistical software analyzes, and represents with x ± s, relatively checks with t between group and carries out significance test.
4. result
4.1 influence to cerebral ischemia reperfusion model (MCAO) rat cerebral infarction scope and nervous symptoms
Postoperative 6h, sham operated rats does not see that dystropy changes, MCAO model group rat is 6h after surgery, hemiplegia sample symptom occurs, mainly shows as to occur that homonymy Huo Na comprehensive (Horner) levies, spontaneous paralysis sideway swivel, mention myasthenia of limbs flexing before the tail offside, counteragent and weaken etc.Administration respectively organize its nervous symptoms of postoperative 6h and the model group comparing difference remarkable, improvement is in various degree all arranged, wherein No. 3 30.0mg/kg group (P＜0.01), No. 3 15.0mg/kg groups, 2 groups of 1 group of embodiment, embodiment and embodiment 3 groups (P＜0.05) are remarkable with the model group comparing difference, and each is organized symptom and the results are shown in Table 2.
Postoperative 24h, model group rat cerebral tissue focus of infarct (being the cerebral infarction scope) can reach 19.1% of full brain weight, compare with model group, organize 1 group of 30mg/kg, embodiment No. 1,3 groups of 2 groups of embodiment and embodiment have significant differences (P＜0.01) to reducing the rat cerebral infarction degree, No. 1 group 15mg/kg; No. 3 groups 15.0mg/kg, 7.5mg/kg; No. 5 groups, No. 6 groups alleviate the rat cerebral infarction degree and to have significant difference (P＜0.05), the results are shown in Table 2.
The influence of table 2 pair MCAO rat cerebral infarction scope and nervous symptoms (x ± s)
Annotate: compare with model group, * * represents P＜0.01, and * represents P＜0.05.
Conclusion: can find out from table 2, the rat that 2 groups of 1 group of embodiment, embodiment and embodiment are 3 groups is obviously less at the less prerequisite hypencephalon infarction size of taking dose, compare other each group, the effect that its rat infraction degree alleviates is ideal, and compares with model group and all to have significant difference (P＜0.01).
Simultaneously, from the nervous symptoms score values of 2 groups of 1 group of embodiment, embodiment and 3 groups of rats of embodiment also as can be seen, pharmaceutical composition of the present invention has good effect for alleviating the cardiovascular and cerebrovascular disease symptom.
4.2 influence to cerebral ischemia reperfusion model (MCAO) rat blood serum SOD vigor and MDA content
Model group serum activity of SOD and sham operated rats be its active obviously reduce (P＜0.05) relatively, other each dosage groups and model group comparison SOD vigor obviously raise (P＜0.01 or P＜0.05).This test model group rat blood serum MDA content and sham operated rats be no significant difference relatively, and other each administration groups compare no significant difference with model group except that No. 4 groups, the results are shown in Table 3.
The influence of table 3 pair MCAO rat blood serum SOD vigor and MDA content (x ± s)
Annotate: compare with model group, * * represents P＜0.01, and * represents P＜0.05.
5. conclusion:
Above-mentioned result of the test shows: pharmaceutical composition of the present invention; reduce at taking dose under one times the situation; than singly using, singly use, singly use, singly using with the dosage Folium Ginkgo extract and add Radix Notoginseng extract, singly use to add aspirin or singly use and add aspirin to alleviating cerebral ischemia reperfusion model (MCAO) rat nervous symptoms damage with the dosage Radix Notoginseng extract with the dosage Folium Ginkgo extract with the dosage aspirin with the dosage Radix Notoginseng extract with the dosage Folium Ginkgo extract; reduce the brain infarction area scope; improve serum activity of SOD, cerebral ischemia is had the better protection effect.This shows, Folium Ginkgo extract, Radix Notoginseng extract and aspirin compatibility have been share good synergism, the therapeutic effect of cerebral ischemia cerebral infarction all is significantly increased.In addition, pharmaceutical composition of the present invention is when heightening the effect of a treatment, and taking dose significantly reduces, and has reduced the toxicity of medicine, has increased the safety of medication.
Claims (10)
1. a pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is characterized in that, is made up of following raw materials by weight percent: Folium Ginkgo extract 0.1%～99.8%, Radix Notoginseng extract 0.1%～99.8% and aspirin 0.1%～99.8%.
2. the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 1 is characterized in that, is made up of following raw materials by weight percent: Folium Ginkgo extract 15%～35%, Radix Notoginseng extract 15%～35% and aspirin 30%～70%.
3. the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 2 is characterized in that, is made up of following raw materials by weight percent: Folium Ginkgo extract 15%, Radix Notoginseng extract 15% and aspirin 70%.
4. the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 2 is characterized in that, is made up of following raw materials by weight percent: Folium Ginkgo extract 33.0%, Radix Notoginseng extract 34.0% and aspirin 33.0%.
5. the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 2 is characterized in that, is made up of following raw materials by weight percent: Folium Ginkgo extract 26%, Radix Notoginseng extract 26% and aspirin 48%.
6. according to the pharmaceutical composition of each described treatment cardiovascular and cerebrovascular disease of claim 1～5, it is characterized in that, the weight percentage of total flavones is 24%～90% in the described Folium Ginkgo extract, the weight percentage 6%～50% of the total lactone of Semen Ginkgo, the total ginkgolic acids weight content is less than 10ppm.
7. according to the pharmaceutical composition of each described treatment cardiovascular and cerebrovascular disease of claim 1～5, it is characterized in that the weight percentage of Radix Notoginseng total arasaponins is 55%～90% in the described Radix Notoginseng extract.
8. according to the pharmaceutical composition of each described treatment cardiovascular and cerebrovascular disease of claim 1～5, it is characterized in that, described Radix Notoginseng extract is pulverized the back ethanol extraction by Radix Notoginseng, extracting solution reclaims and is added on the macroporous adsorptive resins after ethanol also concentrates, water and ethanol elution successively, collect ethanol elution, reclaim the ethanol after drying and make.
9. according to the pharmaceutical composition of each described treatment cardiovascular and cerebrovascular disease of claim 1～5, it is characterized in that, described Folium Ginkgo extract is pulverized the back ethanol extraction by Folium Ginkgo, extracting solution reclaims and is added on the macroporous adsorptive resins after ethanol also concentrates, water and ethanol elution successively, collect ethanol elution, reclaim the ethanol after drying and make.
10. according to the pharmaceutical composition of each described treatment cardiovascular and cerebrovascular disease of claim 1～5, it is characterized in that described pharmaceutical composition is made any dosage form in tablet, capsule, drop pill, granule, the suppository.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101539865A CN101708204B (en) | 2009-11-30 | 2009-11-30 | Medicinal composition for treating cardio-cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101539865A CN101708204B (en) | 2009-11-30 | 2009-11-30 | Medicinal composition for treating cardio-cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101708204A true CN101708204A (en) | 2010-05-19 |
| CN101708204B CN101708204B (en) | 2012-04-25 |
Family
ID=42401025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101539865A Expired - Fee Related CN101708204B (en) | 2009-11-30 | 2009-11-30 | Medicinal composition for treating cardio-cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101708204B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397310A (en) * | 2011-09-29 | 2012-04-04 | 玉溪市维和维生堂保健食品有限公司 | Pseudo-ginseng triol set and ginkgo biloba leaf extract composition, and preparation and application thereof |
| CN107854505A (en) * | 2017-09-25 | 2018-03-30 | 中国医学科学院药用植物研究所 | Pseudo-ginseng and aspirin combination or the new application combined |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1228051C (en) * | 2003-06-30 | 2005-11-23 | 王付兰 | Medicinal composition for treating cardiovascular disease |
| CN1679942A (en) * | 2005-02-04 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Compound preparation of aspirin and ginkgo biloba extract and use thereof |
-
2009
- 2009-11-30 CN CN2009101539865A patent/CN101708204B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397310A (en) * | 2011-09-29 | 2012-04-04 | 玉溪市维和维生堂保健食品有限公司 | Pseudo-ginseng triol set and ginkgo biloba leaf extract composition, and preparation and application thereof |
| CN102397310B (en) * | 2011-09-29 | 2015-08-19 | 玉溪市维和维生堂保健食品有限公司 | Notoginseng triol group and ginkgo leaf extract composition and preparation and purposes |
| CN107854505A (en) * | 2017-09-25 | 2018-03-30 | 中国医学科学院药用植物研究所 | Pseudo-ginseng and aspirin combination or the new application combined |
| CN107854505B (en) * | 2017-09-25 | 2020-12-25 | 中国医学科学院药用植物研究所 | New use of combination of pseudo-ginseng and aspirin |
| US11883452B2 (en) | 2017-09-25 | 2024-01-30 | Chinese Academy Of Medical Sciences Institute Of Medicinal Plant Development | Use of combination or composition of Radix et Rhizoma Notoginseng and aspirin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101708204B (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100473404C (en) | Hypertension treating Chinese medicine preparation | |
| CN103830538A (en) | Chinese medicinal composition for treating cerebral thrombosis and preparation method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN101708204B (en) | Medicinal composition for treating cardio-cerebrovascular diseases | |
| CN104147536A (en) | Medicine composition for treating haemorrhoids and preparation method thereof | |
| CN109820943B (en) | Zhuang medicine preparation for treating gout and preparation method thereof | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101596196A (en) | The compositions of ligustrazine and danshensu and pharmacology activity research thereof | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN106361829B (en) | Traditional Chinese medicine composition and preparation for treating ischemic stroke and preparation method thereof | |
| CN102274291B (en) | Chinese medicinal preparation for treating stroke and production method thereof | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN102139005B (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN101129431A (en) | Traditional Chinese medicine composition for preventing and controlling cardiovascular disease and relative disease, method of preparing the same and application of the same | |
| CN103948767A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, as well as preparation method and application thereof | |
| CN103768454A (en) | Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof | |
| CN103989969A (en) | Traditional Chinese medicament for treating wind-cold obstruction type cervical spondylotic radiculopathy and preparation method thereof | |
| CN104667183A (en) | Medicine preparation for treating damp-heat evil stagnation type pyogenic osteomyelitis and preparation method of medicine preparation | |
| CN104027719A (en) | Traditional Chinese medicine compound composition capable of treating hypersplenism liver-depression and spleen-deficiency type diseases caused by infectious endocarditis and preparation method thereof | |
| CN107233410B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN103933154A (en) | Traditional Chinese medicine composition for treating gout disease and preparation method thereof | |
| CN103191243A (en) | Application of medicament composition composed of coptis chinensis and fructus evodiae and preparation method of medicament composition | |
| CN114558058B (en) | Traditional Chinese medicine composition for treating vascular dementia and preparation thereof | |
| CN101940570A (en) | Composite of ligustrazine phosphate and danshensu and application thereof | |
| CN102688308B (en) | Traditional Chinese medicine composition for ischemic stroke treatment as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20181130 |